)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Infant Bacterial Therapeutics
Infant Bacterial Therapeutics (IBT) investor relations material
Infant Bacterial Therapeutics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary26 Aug, 2026
Executive summary
Continued focus on bringing IBP-9414, a live biotherapeutic for premature infants, to market, with regulatory and manufacturing milestones progressing in both the EU and US.
IBP-9414 demonstrated a 27% reduction in all-cause mortality in preterm infants in Phase III, with significant regulatory designations received.
No revenue generated; operations remain pre-commercial, with ongoing R&D and regulatory expenses.
Financial highlights
Net sales were SEK 0 for both Q2 and H1 2026, unchanged from prior periods.
Operating loss for Q2 2026 was SEK -30.1 million (vs. -20.1 million Q2 2025); H1 2026 operating loss was SEK -53.6 million (vs. -37.6 million H1 2025).
Result after tax for H1 2026 was SEK -52.7 million (vs. -35.9 million H1 2025).
Cash flow for H1 2026 was SEK -35.6 million (vs. -43.9 million H1 2025); cash balance at June 30, 2026 was SEK 108.6 million.
Equity per share at June 30, 2026 was SEK 3.94 (vs. 9.97 June 30, 2025); equity ratio was 44% (vs. 70%).
Outlook and guidance
Goal remains to submit the Biologics License Application (BLA) for IBP-9414 in the US by year-end 2026.
Capital is considered sufficient until market approval is obtained.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Infant Bacterial Therapeutics
- Operating loss widened in Q1 2026 as IBP-9414 nears FDA submission and commercialization.IBT
Q1 2026 - Losses narrowed and IBP-9414 advanced toward FDA approval, with strong cash reserves maintained.IBTQ4 2025
- IBP-9414 achieved 27% lower mortality in preterm infants; regulatory filings planned for 2026.IBTQ3 2025
- FDA review of IBP-9414 progresses as losses narrow and launch preparations intensify.IBTQ2 2025
- Phase 3 trial for IBP-9414 cut infant mortality, supporting IBT's regulatory push.IBTQ3 2024
- 27% reduction in all-cause mortality in preterm infants, despite missed primary endpoints.IBTStudy Update
- Phase 3 trial for IBP-9414 completed; results expected Q3 2024 amid higher H1 losses.IBTQ2 2024
- FDA Breakthrough Therapy Designation for IBP-9414 accelerates IBT's market path.IBTQ1 2025
- IBP-9414 advanced to regulatory submission with increased losses but strong cash reserves.IBTQ4 2024
Next Infant Bacterial Therapeutics earnings date
Q3 202613 Nov, 2026
Infant Bacterial Therapeutics
Next Infant Bacterial Therapeutics earnings date
Q3 202613 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Infant Bacterial Therapeutics is a Sweden-based pharmaceutical company focused on developing microbiome-based treatments for diseases affecting premature infants and children. Its primary focus is on preventing necrotizing enterocolitis and other serious conditions using live bacterial therapies. Infant Bacterial Therapeutics is headquartered in Stockholm, Sweden, and its shares are listed on the NASDAQ Stockholm.